Business
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor,
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"text","content":"On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023 Positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer to be presented ahead of original guidance at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Announced collaborations with Foundation Medicine and Roche Diagnostics to advance the development of azenosertib Diana Hausman, M.D., oncology veteran with over two decades of clinical development and executive experience, appointed to Board of Directors Funda Meric-Bernstam, M.D., a widely recognized Phase 1 trial expert and experimental therapeutics researcher in oncology, appointed to Scientific Advisory Board $392 million cash balance as of March 31, 2023, with projected cash runway into the second quarter of 2025 NEW YORK and SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended March 31, 2023, and highlighted recent corporate accomplishments. “We believe that azenosertib has the potential to benefit large numbers of patients who are facing difficult-to-treat cancers. As a result, our highest priority remains the successful execution of our development strategy for this promising therapeutic,” said Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis. “We began the year by initiating enrollment in our Pfizer-partnered clinical trial combining azenosertib with the BEACON regimen in BRAF V600E mutant metastatic colorectal cancer. At AACR in April, we presented preclinical data supporting the use of CCNE1 amplification and/or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib. We are driving toward two additional milestones for azenosertib in the first half of the year – disclosing our monotherapy dose, and sharing positive clinical data from our chemotherapy combination trial in ovarian cancer at ASCO in June.” The Company also announced the appointment of Diana Hausman, M.D., to the Board of Directors. “I share Zentali...